Fractyl Health Receives Nasdaq Delisting Notice After Six-Month Cure Fails
Listing At Risk
Company Background
Fractyl Health is a Burlington, Massachusetts clinical-stage company developing two candidates for obesity and type 2 diabetes: Revita, a one-time endoscopic procedure designed to maintain weight loss in patients who discontinue GLP-1 drugs, and Rejuva, a gene therapy platform whose lead candidate, RJVA-001, has received clinical trial authorization in the Netherlands to begin first-in-human testing. The company has generated no revenue, and total operating expenses ran to roughly $39.9 million in the first half of 2026. Stockholders' equity turned negative, standing at a deficit of $1.7 million at June 30, 2026.
The company entered 2026 with approximately $81.5 million in cash after a $60 million underwritten equity offering priced in September 2025. By June 30, 2026, that balance had fallen to $47.1 million. Management has consistently guided that existing cash will fund operations into early 2027, but with Adjusted EBITDA losses running at roughly $16 million per quarter, the runway is measured in months, not years.
The September 2025 offering was priced at exactly $1.00 per share — Nasdaq's minimum bid threshold. That the company needed to raise capital at the floor price underscored the market's valuation of the business before the compliance clock ever started ticking.
What Was Disclosed
Nasdaq formally notified Fractyl on September 10, 2026 that its securities are subject to delisting, after the company failed to regain compliance with the minimum bid price requirement by the September 9 deadline. The non-compliance period began March 13, 2026, when Nasdaq sent an initial notice that the stock had closed below $1.00 for 30 consecutive business days. Under Nasdaq rules, the company had 180 calendar days to achieve 10 consecutive business days of closes at or above $1.00. It did not.